CELGENE STOCK ANALYSIS: Fighting Cancer

Celgene is the third largest biotech company in the world after Amgen and Gilead Sciences

Celgene is focused on oncology, that is, the treatment of cancers.

42% of revenue of Celgene comes from Revlimid which is used by patients with multiple myeloma.

Bristol-Myers Squib (BMS) is going to acquire Celgene in the coming months and there is the opportunity to make an arbitrage trade.